[AMRN] Amarin Corporation plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.11 Change: 0.12 (4.01%)
Ext. hours: Change: 0 (0%)

chart AMRN

Refresh chart

Strongest Trends Summary For AMRN

AMRN is in the medium-term up 42% in 7 months. In the long-term up 1843% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Fundamental Ratios
Shares Outstanding EPS-0.33 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 26.39% Sales Growth - Q/Q-3.32% P/E-8.88
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.56% ROE99.49% ROI-38.89%
Current Ratio4.46 Quick Ratio4.08 Long Term Debt/Equity1.49 Debt Ratio-0.69
Gross Margin63.04% Operating Margin-164.67% Net Profit Margin-103.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities54.3 M Cash From Investing Activities Cash From Operating Activities-12.64 M Gross Profit10.31 M
Net Profit-31.13 M Operating Profit-27.05 M Total Assets215.34 M Total Current Assets189.75 M
Total Current Liabilities42.53 M Total Debt233.48 M Total Liabilities277.16 M Total Revenue15.93 M
Technical Data
High 52 week23.16 Low 52 week12.41 Last close15.86 Last change2.65%
RSI49.7 Average true range0.66 Beta0.52 Volume2.65 M
Simple moving average 20 days3.48% Simple moving average 50 days1.83% Simple moving average 200 days-10.53%
Performance Data
Performance Week12.08% Performance Month-8.06% Performance Quart-24.73% Performance Half-13.76%
Performance Year-19.29% Performance Year-to-date16.53% Volatility daily2.47% Volatility weekly5.52%
Volatility monthly11.31% Volatility yearly39.17% Relative Volume527.59% Average Volume7.79 M
New High New Low

News

2020-06-01 13:38:28 | Hedge Funds Aren’t Done Buying Amarin Corporation plc AMRN

2020-06-01 07:00:10 | Amarin Plans to Increase VASCEPA® icosapent ethyl Promotion and Education

2020-05-28 17:02:24 | Will Courts Reverse Earlier Ruling on Amarin Patents? Analyst Weights In

2020-05-22 13:23:00 | FDA Approves Generic Version of Amarin's Blockbuster Fish Oil Capsules

2020-05-22 13:15:48 | Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement

2020-05-22 09:07:00 | Amarin Stock Is Falling. A Competitor Got Approval for a Generic Version of Its Heart Drug.

2020-05-22 08:45:25 | Amarin Down 10% in Pre-Market On Generic Approval

2020-05-22 08:22:00 | 1 Biotech Stock to Avoid at All Costs

2020-05-22 07:10:20 | The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

2020-05-21 16:07:00 | HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® Icosapent Ethyl against COVID-19

2020-05-21 16:05:10 | Amarin Supports Trial to Investigate the Effects of VASCEPA® icosapent ethyl in the Treatment of COVID-19

2020-05-19 05:07:00 | Is Amarin Stock a Buy?

2020-05-15 18:14:31 | Can Amarin AMRN Overcome Its Patent Headwinds? 5-Star Analyst Weighs In

2020-05-14 14:50:10 | VASCEPA® icosapent ethyl Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study

2020-05-09 06:44:00 | If You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have Now

2020-05-06 11:26:03 | Iovance IOVA Q1 Loss Wider Than Expected, Revenues Nil

2020-05-05 12:17:25 | Amarin AMRN Stock Could Stage a Rebound to $15, Says Analyst

2020-05-04 18:43:15 | Amarin AMRN: All Eyes on Vascepa Appeal Verdict

2020-05-04 05:26:09 | Amarin's Shares March Higher, Can It Continue?

2020-05-01 10:51:02 | Amarin's AMRN Q1 Loss In Line With Estimates, Sales Beat

2020-05-01 03:35:21 | Edited Transcript of AMRN earnings conference call or presentation 30-Apr-20 11:30am GMT

2020-04-30 20:30:36 | Amarin Corporation plc AMRN Q1 2020 Earnings Call Transcript

2020-04-30 09:08:01 | Amarin AMRN Meets Earnings Estimates in Q1, Revenues Tops

2020-04-30 07:19:06 | The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

2020-04-30 05:00:10 | Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations

2020-04-29 11:54:03 | Is a Beat in Store for Amarin AMRN This Earnings Season?

2020-04-29 10:05:02 | Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

2020-04-28 07:00:10 | Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020

2020-04-24 18:45:00 | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm

2020-04-21 16:25:00 | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm

2020-04-16 08:33:52 | Cramer Shares His Thoughts On Yext, Workday And More

2020-04-15 06:46:08 | Here's Why Amarin NASDAQ:AMRN Can Manage Its Debt Despite Losing Money

2020-04-14 07:59:06 | The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership

2020-04-14 03:51:57 | Amarin Reports Strong 1Q Vascepa Sales; Plans Patent Appeal For May

2020-04-14 00:54:29 | Edited Transcript of AMRN earnings conference call or presentation 13-Apr-20 8:30pm GMT

2020-04-13 18:17:00 | Amarin Shares Recover Somewhat After US Patent Setback

2020-04-08 16:05:10 | Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update

2020-04-06 11:44:55 | Amarin AMRN Will Make Excellent Takeover Target, Says Analyst

2020-04-03 13:56:00 | INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm

2020-04-02 13:30:00 | SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm

2020-04-02 09:55:01 | Is Amarin AMRN Stock a Solid Choice Right Now?

2020-04-01 12:15:00 | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $500,000 to Contact the Firm

2020-04-01 11:01:47 | Judge’s Record Looks Unpromising for Amarin’s Appeal; Analyst Remains Bullish

2020-03-31 18:19:00 | INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm

2020-03-31 12:00:52 | Judicial Ruling Guts Amarin AMRN Stock; What’s Next?

2020-03-31 10:12:02 | Amarin's Stock Plunges Following Unfavorable Patent Ruling

2020-03-31 08:50:10 | Amarin Investors Who Lost Money Should Contact Block & Leviton: The Firm Is Investigating Securities Fraud at the Company

2020-03-31 08:49:00 | Amarin's stock plummets on heavy volume after court rules in favor of makers of generic Vascepa

2020-03-31 08:26:15 | The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions

2020-03-31 07:20:00 | Halliburton Soars, Amarin Slumps as Chinese Data Show Signs of Life